Prostate cancer

The aim of the Integrated Genome Research Project (IG) Prostate Cancer is to utilize the high-throughput technologies that were established within the NGFN towards an improved clinical management of prostate cancer. In order to create the critical mass and synergies required to achieve substantial improvements in this field, we have joined the forces of internationally renowned partners in molecular genome analysis, urology, and pathology.
The IG Prostate Cancer will cover the entire workflow from the identification of novel molecular marker signatures to data validation in large-scale retrospective analyses as well as a prospective clinical study. We expect to generate validated molecular markers for improving the detection of tumors and for assessing the risk of cancer progression. To optimally exploit these markers, we will develop technologies for tumor detection in patient tissue and serum. We will perform in-depth functional analysis of biomarkers from cell lines up to the level of mammalian model organisms. With the comprehensive understanding of gene functions enabled by experimental data and bioinformatic network generation and data modeling, the results will be crucial to determine optimal diagnostic and therapeutic strategies for patient treatment.



Additional relevant Internet links:
ig-prostate-cancer